Alexandra Zimmer

Featured in: Favicon

nature.com Favicon

thelancet.com Favicon

futuremedicine.com Favicon

onlinelibrary.wiley.com Favicon

Articles

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial - Nature Medicine

Sep 14, 2024 | nature.com | Katia Khoury |Hope Rugo |Rita Nanda |Alexandra Zimmer |Judy Boughey |Christos Vaklavas | +11 more

AbstractAmong the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes. Here we tested datopotamab–deruxtecan (Dato-DXd) in the I-SPY2.2 trial for patients with high-risk stage 2/3 breast cancer.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →